Shimadzu Corporation and the Earle A. Chiles Research Institute, a division of Providence Cancer Institute (Providence) in Portland, Oregon, have entered into a joint research agreement to apply mass spectrometry technology to develop tools for personalized cancer immunotherapeutics.   Shimadzu and Providence will develop technologies to reliably identify cancer antigens recognized by an individual’s immune system, and to analyze the pharmacokinetics of immunotherapy drugs, with the goal of br...